Highlights:
- Australian FY23 sales of A$1.16 M (478% increase on FY22 sales)
- USA FY23 Travelan sales of A$643 k (28% increase on FY22 sales)
- Global FY23 sales of A$1.80 M (136% increase on FY22 sales)
MELBOURNE, Australia, July 05, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales (unaudited net sales) results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan and Protectyn.
Sales of Travelan and Protectyn increased by 136% in FY23 to AUD $1.80 M, compared to AUD $765 k in FY22.
In Australia, Travelan and Protectyn sales for FY23 were AUD $1.16 M, a 478% increase on FY22 sales (AUD $201 k). Travelan sales increase as overseas travel rebounds. Australian resident short term departures in April 2023 were 82% of those in April 2019 (Australian Bureau of Statistics).
Immuron previously reported that strong sales of Travelan may result in short term stock outages in some wholesalers and pharmacies in the June 2023 quarter. This did occur. While Immuron does have inventory of Travelan Australia ready to release, it is unable to do so until it has received GMP Clearance from the Therapeutic Goods Administration (TGA). Even though Immuron has transferred and validated the transfer of packaging to another supplier which has a valid/current GMP certificate from the TGA, the TGA is unable to give Immuron a timeline for GMP Clearance. The TGA advises that it is experiencing extremely high volumes of GMP Clearance extension applications which is resulting in delays to processing timeframes.1 Immuron shall continue to press for an early resolution of this issue with the TGA.
USA Travelan FY23 sales were AUD $643 k, a 28% increase on FY22 sales (AUD $501 k). This growth was attributable to increasing sales in both Passport Health Travel Clinics and distributor sales. FY23 sales were impacted by supply constraints. These have been resolved. Immuron has inventory of Travelan USA on hand, sufficient to meet the needs of its current customers and to expand into new market segments. Immuron has shipped inventory to Amazon with launch anticipated in the next couple of weeks.
Immuron is focused on growing sales of its commercial products, expanding its portfolio of products and has a strong existing pipeline.
- Australian Government Department of Health and Aged Care Therapeutic Goods Administration
This release has been authorised by the directors of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit:
亮點：
- 澳大利亞23財年的銷售額爲116萬澳元（比22財年的銷售額增長478％）
- 美國23財年Travelan的銷售額爲6.43萬澳元（比22財年的銷售額增長28％）
- 2013財年的全球銷售額爲180萬澳元（比22財年的銷售額增長136％）
澳大利亞墨爾本，2023年7月5日（GLOBE NEWSWIRE）——總部位於澳大利亞的全球整合生物製藥公司Immuron Limited（澳大利亞證券交易所股票代碼：IMC；納斯達克股票代碼：IMR）欣然宣佈其非處方胃腸道和消化系統健康免疫補充劑Travelan和Protectyn的23財年銷售額（未經審計的淨銷售額）業績。
Travelan和Protectyn的銷售額在23財年增長了136％，達到180萬澳元，而22財年的銷售額爲7.65萬澳元。
在澳大利亞，Travelan和Protectyn在2013財年的銷售額爲116萬澳元，比22財年的銷售額（2.01萬澳元）增長了478％。隨着海外旅行的反彈，Travelan的銷售額有所增加。2023年4月澳大利亞居民的短期離境人數佔2019年4月的82％（澳大利亞統計局）。
Immuron此前曾報告稱，Travelan的強勁銷售可能會導致一些批發商和藥房在2023年6月的季度出現短期庫存短缺。這確實發生了。儘管Immuron確實準備發佈Travelan Australia的庫存，但在獲得治療用品管理局（TGA）的GMP許可之前，它無法發佈。儘管Immuron已將包裝轉移並驗證了向另一家擁有TGA有效/當前GMP證書的供應商，但TGA無法向Immuron提供GMP許可的時間表。TGA表示，它正在經歷大量的GMP許可延期申請，這導致了處理時間表的延遲。1 Immuron 將繼續敦促儘早與 TGA 解決這個問題。
USA Travelan 2013財年的銷售額爲6.43萬澳元，比22財年的銷售額（5.01萬澳元）增長了28％。這一增長歸因於Passport Health Travel Clinics的銷售額和分銷商銷售的增長2013 財年的銷售受到供應限制的影響。這些問題已得到解決。Immuron手頭有Travelan USA的庫存，足以滿足其當前客戶的需求並擴展到新的細分市場。Immuron已向亞馬遜運送庫存，預計將在未來幾周內推出。
Immuron專注於增加其商業產品的銷售，擴大其產品組合，並且擁有強大的現有產品線。
- 澳大利亞政府衛生和老年護理部治療用品管理局
此版本已獲得 Immuron Limited 董事的授權。
COMP任何騙局T行動：
史蒂芬·萊德阿莫爾
首席執行官
Ph: +61 (0) 3 9824 5254
info@immuron.com |
關於 Immuron
Immuron Limited（ASX: IMC，納斯達克股票代碼：IMRN）是一家澳大利亞生物製藥公司，專注於開發和商業化用於治療炎症介導和傳染病的口服靶向多克隆抗體。
欲瞭解更多信息，請訪問：
